Dexter Series E: $90M to Make Sense of Robotic Surgery - EuroUS Ventures SA

Dexter Series E: $90M to Make Sense of Robotic Surgery

February 14, 2022|DistalMotion|

Distalmotion, a Swiss-based medical device company, received European CE Mark for its surgical robot Dexter. Dexter combines the affordability of laparoscopy with the benefits of robotic surgery.

Distalmotion

https://www.distalmotion.com/dexter-series-e-90m-to-make-sense-of-robotic-surgery/

more news …

view related content

Apr 22

2025

Category : DistalMotion

Distalmotion Advances US Expansion of its DEXTER® Surgical Robot with Clinical Milestones and System Enhancements
read more
Oct 29

2024

Category : DistalMotion

Surgical robot gets greenlight to enter the US market
read more
Apr 24

2023

Category : DistalMotion

Distalmotion raises $150M to accelerate FDA approval and clinical experience
read more